NCT03449264 Development of Clinical and Biological Database
| NCT ID | NCT03449264 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institut du Cancer de Montpellier - Val d'Aurelle |
| Condition | Digestive Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 4,000 participants |
| Start Date | 2017-07-27 |
| Primary Completion | 2027-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 4,000 participants in total. It began in 2017-07-27 with a primary completion date of 2027-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The BCB is a tool: * for research in analytical and public health epidemiology, biological research and for the development of data useful for clinical research and therapeutic trials; * to help scientists understand and explain phenomena ranging from the interaction of molecules to the whole metabolism of the organism in normal and pathological situations; * to identify potential strategies for prevention, diagnosis, management and analysis of cancer subtypes. The creation of a broad clinical and biological prospective base dedicated to different types of cancer is essential for the development of such projects.
Eligibility Criteria
Inclusion Criteria: * Age\> at 18 years old, * Patient with invasive or in situ tumor pathology (proven or suspected) any stage confounded, * Patient in ICM at diagnosis * a digestive cancer (esophagus, stomach, pancreas, colon, rectum, anal canal) or * gynecological cancer (ovary, endometrium, cervix) or * breast cancer or * sarcoma. * Naïve patient of any treatment for the present cancer, * Patient requiring treatment involving at least one (or more) tumor surgery (s) * Patient who has accepted supplementary blood samples, * Patient having given his informed, written and express consent. Exclusion Criteria: * Patient not affiliated to a social protection scheme, * Patient whose regular follow-up is a priori impossible for psychological, familial, social or geographical reasons, * Pregnant and / or nursing women, * Subject under tutelage, curatorship or safeguard of justice, * Patient in an emergency situation.
Contact & Investigator
jean pierre Bleuse
STUDY CHAIR
Institut régional du Cancer de Montpellier
Frequently Asked Questions
Who can join the NCT03449264 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Digestive Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03449264 currently recruiting?
Yes, NCT03449264 is actively recruiting participants. Contact the research team at david.azria@icm.unicancer.fr for enrollment information.
Where is the NCT03449264 trial being conducted?
This trial is being conducted at Montpellier, France.
Who is sponsoring the NCT03449264 clinical trial?
NCT03449264 is sponsored by Institut du Cancer de Montpellier - Val d'Aurelle. The principal investigator is jean pierre Bleuse at Institut régional du Cancer de Montpellier. The trial plans to enroll 4,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.